Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.

Détails

ID Serval
serval:BIB_CA7646E40C03
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Périodique
Clinical cancer research
Auteur(s)
Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., Tannock A.I.
Collaborateur(s)
TAX-327 investigators
ISSN
1078-0432 (Print)
ISSN-L
1078-0432
Statut éditorial
Publié
Date de publication
01/05/2008
Peer-reviewed
Oui
Volume
14
Numéro
9
Pages
2763-2767
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
The TAX-327 study randomized 1,006 men with metastatic hormone-refractory prostate cancer to receive 3-weekly docetaxel, weekly docetaxel, or mitoxantrone, each with prednisone.
We used the TAX-327 database to address (a) the relationship between quality of life (QoL) and pain; (b) whether minimally symptomatic patients benefit from treatment or have treatment-related decline in QoL; (c) the relationships between prostate-specific antigen (PSA) response, pain response, and QoL response; (d) the times at which these responses are first observed; and (e) whether PSA, pain, and/or QoL response predict for overall survival.
At baseline, 374 of 815 men assessed for QoL had major pain; of these, 92% had substantial impairment of QoL compared with 75% without major pain (P < 0.001). Men with minimal symptoms had prolonged survival (median, 25.6 months) compared with symptomatic patients (median, 17.1 months; P = 0.009); they were more likely to have initial deterioration of QoL if treated with weekly docetaxel. PSA response and pain response, but not QoL response, were independently associated with survival in landmark analysis. Median times to PSA and pain response were 44 and 27 days, respectively; some men had initial increase in serum PSA before subsequent decline.
Symptoms other than pain contribute to impaired QoL in men with hormone-refractory prostate cancer. Those with minimal symptoms have prolonged survival. Both pain and PSA response are associated with survival but are not adequate to use as surrogate end points in phase 3 studies. Early increases in serum PSA (up to 12 weeks) should be ignored when determining response or progression.

Mots-clé
Aged, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/therapeutic use, Antineoplastic Agents, Hormonal/therapeutic use, Humans, Male, Mitoxantrone/administration & dosage, Mitoxantrone/therapeutic use, Pain, Prednisone/administration & dosage, Prednisone/therapeutic use, Prostate-Specific Antigen/blood, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms/mortality, Quality of Life, Taxoids/administration & dosage, Taxoids/therapeutic use
Pubmed
Open Access
Oui
Création de la notice
21/12/2016 13:40
Dernière modification de la notice
20/08/2019 16:45
Données d'usage